Fabien Mignot1, Zahra Ajgal2, Hoping Xu3, Arthur Geraud2, Jia Yi Chen4, Frédérique Mégnin-Chanet5, Youlia Kirova2. 1. Département d'Oncologie Radiothérapie, Institut Curie, Paris, France. Electronic address: fabien.mignot86@gmail.com. 2. Département d'Oncologie Radiothérapie, Institut Curie, Paris, France. 3. Département d'Oncologie Radiothérapie, Institut Curie, Paris, France; Department of Radiation Oncology, Ruijin Hospital, Shanghai, China. 4. Department of Radiation Oncology, Ruijin Hospital, Shanghai, China. 5. Département de recherche, Institut Curie, Orsay, France.
Abstract
BACKGROUND: Over the past few years, anti-HER2 targeted therapies have proven to be a key treatment in the management of human epidermal growth receptor 2 (HER2)-positive breast cancers, as well as gastrointestinal tract tumors and head and neck tumors. Anti-HER2 therapies administered alone or in combination with chemotherapy have been extensively studied, but only limited robust data are available concerning the safety and efficacy of anti-HER2 molecules in combination with radiotherapy. METHODS: We searched on Medline, Embase and Cochrane databases the articles providing data on the concomitant association between the antiHER2 therapies used in clinical practice (trastuzumab, pertuzumab, lapatinib and T-DM1) with radiotherapy. The articles were selected according to their pre-clinical and clinical relevance. RESULTS: The trastuzumab-irradiation combination is the most studied, with a focus on the cardiac toxicity. The combination of lapatinib-irradiation was particularly studied in the context of cerebral metastases of HER2-positive breast cancer. The data on pertuzumab and T-DM1 were poor and are mainly case reports. CONCLUSION: To date, reliable conclusions about the toxicity and/or efficacy of concomitant irradiation with anti-HER2 therapies are difficult to make due to the heterogeneity of the data in the literature and need to be confirmed on a larger scale and long term follow-up. Nevertheless, no serious adverse events are reported and the toxicity profile seems to be manageable.
BACKGROUND: Over the past few years, anti-HER2 targeted therapies have proven to be a key treatment in the management of human epidermal growth receptor 2 (HER2)-positive breast cancers, as well as gastrointestinal tract tumors and head and neck tumors. Anti-HER2 therapies administered alone or in combination with chemotherapy have been extensively studied, but only limited robust data are available concerning the safety and efficacy of anti-HER2 molecules in combination with radiotherapy. METHODS: We searched on Medline, Embase and Cochrane databases the articles providing data on the concomitant association between the antiHER2 therapies used in clinical practice (trastuzumab, pertuzumab, lapatinib and T-DM1) with radiotherapy. The articles were selected according to their pre-clinical and clinical relevance. RESULTS: The trastuzumab-irradiation combination is the most studied, with a focus on the cardiac toxicity. The combination of lapatinib-irradiation was particularly studied in the context of cerebral metastases of HER2-positive breast cancer. The data on pertuzumab and T-DM1 were poor and are mainly case reports. CONCLUSION: To date, reliable conclusions about the toxicity and/or efficacy of concomitant irradiation with anti-HER2 therapies are difficult to make due to the heterogeneity of the data in the literature and need to be confirmed on a larger scale and long term follow-up. Nevertheless, no serious adverse events are reported and the toxicity profile seems to be manageable.
Authors: Dina V Hingorani; Matthew K Doan; Maria F Camargo; Joseph Aguilera; Seung M Song; Donald Pizzo; Daniel J Scanderbeg; Ezra E W Cohen; Andrew M Lowy; Stephen R Adams; Sunil J Advani Journal: Mol Cancer Ther Date: 2019-10-09 Impact factor: 6.261
Authors: Meghan J Bloom; Patrick N Song; John Virostko; Thomas E Yankeelov; Anna G Sorace Journal: Cancers (Basel) Date: 2022-08-31 Impact factor: 6.575
Authors: Marc D Piroth; David Krug; Felix Sedlmayer; Marciana-Nona Duma; René Baumann; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Rainer Souchon; Vratislav Strnad; Rolf Sauer Journal: Strahlenther Onkol Date: 2020-07-31 Impact factor: 3.621